메뉴 건너뛰기




Volumn 58, Issue 1, 2003, Pages 31-36

What role for intermediate outcomes once cardiovascular prevention is achieved?;Quelle est la place des critères intermédiaires après la démonstration d'une prévention des risques cardiovasculaires?

Author keywords

Clinical trials; Intermediate outcomes; Statins; Surrogate outcomes

Indexed keywords

STATIN;

EID: 0037947447     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2003005     Document Type: Article
Times cited : (3)

References (16)
  • 1
    • 0034741193 scopus 로고    scopus 로고
    • Marqueurs biologiques: Biomarqueurs - Utilisation au cours du développement et pour l'enregistrement des médicaments
    • Gueyffier F, Dib M, Boissel JP. Marqueurs biologiques: biomarqueurs - utilisation au cours du développement et pour l'enregistrement des médicaments. Thérapie 2001; 56: 355-61
    • (2001) Thérapie , vol.56 , pp. 355-361
    • Gueyffier, F.1    Dib, M.2    Boissel, J.P.3
  • 2
    • 0031174157 scopus 로고    scopus 로고
    • Evaluation clinique: Du critère intermédiaire au critère de substitution
    • Boissel JP, Perret L, Bouvenot G, et al. Evaluation clinique: du critère intermédiaire au critère de substitution. Therapie 1997; 52: 281-5
    • (1997) Therapie , vol.52 , pp. 281-285
    • Boissel, J.P.1    Perret, L.2    Bouvenot, G.3
  • 3
    • 0024520844 scopus 로고
    • Surrogate endpoints in clinical trials: Definition and operational criteria
    • Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8 (4): 431-40
    • (1989) Stat Med , vol.8 , Issue.4 , pp. 431-440
    • Prentice, R.L.1
  • 4
    • 0026593243 scopus 로고
    • Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men: Multiple Risk Factor Intervention Trial Research Group
    • Jan
    • Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men: Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992 Jan; 152 (1): 56-64
    • (1992) Arch Intern Med , vol.152 , Issue.1 , pp. 56-64
    • Neaton, J.D.1    Wentworth, D.2
  • 5
    • 0034686717 scopus 로고    scopus 로고
    • Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity
    • Stamler J, Daviglus ML, Garside DB, et al. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000; 284: 311-31
    • (2000) JAMA , vol.284 , pp. 311-331
    • Stamler, J.1    Daviglus, M.L.2    Garside, D.B.3
  • 6
    • 0026795925 scopus 로고
    • Report of the Conference on low blood cholesterol: Mortality associations
    • Jacobs D, Blackburn H, Higgins M, et al. Report of the Conference on low blood cholesterol: mortality associations. Circulation 1992; 86: 1046-60
    • (1992) Circulation , vol.86 , pp. 1046-1060
    • Jacobs, D.1    Blackburn, H.2    Higgins, M.3
  • 7
    • 0027380992 scopus 로고
    • Cholesterol reduction and the risk for stroke in men: A meta-analysis of randomized, controlled trials
    • Atkins D, Psaty BM, Koepsell TD. Cholesterol reduction and the risk for stroke in men: a meta-analysis of randomized, controlled trials. Ann Intern Med 1993; 119: 136-45
    • (1993) Ann Intern Med , vol.119 , pp. 136-145
    • Atkins, D.1    Psaty, B.M.2    Koepsell, T.D.3
  • 8
    • 0028181730 scopus 로고
    • By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
    • Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-72
    • (1994) BMJ , vol.308 , pp. 367-372
    • Law, M.R.1    Wald, N.J.2    Thompson, S.G.3
  • 9
    • 0028845911 scopus 로고
    • Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program
    • Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92: 2419-25
    • (1995) Circulation , vol.92 , pp. 2419-2425
    • Byington, R.P.1    Jukema, J.W.2    Salonen, J.T.3
  • 10
    • 0037066048 scopus 로고    scopus 로고
    • Relationship between lipid levels and clinical outcomes in the long-term Intervention with pravastatin in ischemic disease (LIPID) trial: To what extent is the reduction in coronary events with pravastatin explained by on-Study lipid levels?
    • Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the long-term Intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-Study lipid levels? Circulation 2002; 105: 1162-9
    • (2002) Circulation , vol.105 , pp. 1162-1169
    • Simes, R.J.1    Marschner, I.C.2    Hunt, D.3
  • 11
    • 17044448335 scopus 로고    scopus 로고
    • Mechanisms of action of statins and their pleiotropic effects
    • Davignon J, Mabile L. Mechanisms of action of statins and their pleiotropic effects. Ann Endocrinol 2001; 62: 101-12
    • (2001) Ann Endocrinol , vol.62 , pp. 101-112
    • Davignon, J.1    Mabile, L.2
  • 12
    • 85031163914 scopus 로고    scopus 로고
    • Bénéfice clinique des traitements hypocholestérolémiants: Méta-analyse des essais thérapeutiques randomisés
    • Cucherat M, Lièvre M, Gueyffier F. Bénéfice clinique des traitements hypocholestérolémiants: méta-analyse des essais thérapeutiques randomisés. Presse Méd 2000; 29: 565-76
    • (2000) Presse Méd , vol.29 , pp. 565-576
    • Cucherat, M.1    Lièvre, M.2    Gueyffier, F.3
  • 13
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial
    • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
    • (2002) Lancet , vol.360 , pp. 7-22
  • 14
    • 0027987849 scopus 로고
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
    • The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
    • (1994) Lancet , vol.344 , pp. 1383-1389
  • 15
    • 0032513878 scopus 로고    scopus 로고
    • Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
    • HOT Study Group
    • Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 35: 1755-62
    • (1998) Lancet , vol.35 , pp. 1755-1762
    • Hansson, L.1    Zanchetti, A.2    Carruthers, S.G.3
  • 16
    • 0037193819 scopus 로고    scopus 로고
    • Risk factor thresholds: Their existence under scrutiny
    • Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2002; 324: 1570-6
    • (2002) BMJ , vol.324 , pp. 1570-1576
    • Law, M.R.1    Wald, N.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.